Program
Immunoglobulins, Intravenous
Also written as “NPB-01”, “TAK-881” and “IVIG”.
Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.
Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 203 open or running | phase 4since Apr 12, 2017 | Sep 8, 2005 | May 16, 2028phase 3 · NCT06076642 |
| Grifolsits history only | 172 open or running | phase 4since Oct 24, 2011 | Sep 13, 2005 | Dec 31, 2027phase 3 · NCT07540221 |
| Nihon Pharmaceuticalits history only | 80 open or running | phase 3since Jul 27, 2011 | Dec 11, 2008 | none ahead |
| Octapharmaits history only | 61 open or running | phase 3since Nov 11, 2009 | Nov 11, 2009 | Nov 2026phase 3 · NCT04640142 |
| CSLits history only | 51 open or running | phase 3since Oct 12, 2011 | Oct 12, 2011 | May 6, 2029phase 2 · NCT07048262 |
| Kedrionits history only | 53 open or running | phase 3since Apr 16, 2012 | Apr 16, 2012 | Dec 2026phase 3 · NCT07059000 |
| Japan Blood Products Organizationits history only | 40 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| GC Biopharmaits history only | 31 open or running | phase 3since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Prothya Biosolutionsits history only | 30 open or running | phase 4since Aug 29, 2007 | Aug 29, 2007 | none ahead |
| Azidus Brasilits history only | 22 open or running | phase 3since Sep 19, 2023 | Sep 19, 2023 | Sep 2028phase 3 · NCT06150833 |
| Benesisits history only | 20 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| Biopharma Plasmaits history only | 20 open or running | phase 3since Jul 15, 2020 | Jul 15, 2020 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Dobri Kiprovits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Evolve Biologicsits history only | 10 open or running | phase 3since Jul 21, 2017 | Jul 21, 2017 | none ahead |
| GammaCanits history only | 10 open or running | phase 2since Feb 19, 2006 | Feb 19, 2006 | none ahead |
| IMMUNOe Research Centersits history only | 10 open or running | phase 4since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Isaac Melamedits history only | 10 open or running | phase 4since Jul 21, 2014 | Jul 21, 2014 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Takeda only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Sep 8, 2005.
- Jan 7, 2009Phase 3 study in DementiaNCT00818662 · 390 enrolled · United States, Canada
- Oct 8, 2010Phase 3 study in Primary Immunodeficiency DiseasesNCT01218438 · 86 enrolled · United States, Canada
- Aug 8, 2011Phase 3 study in Primary Immunodeficiency DiseasesNCT01412385 · 55 enrolled · Austria, Germany, Hungary and more
- Jan 20, 2012Phase 3 study in Alzheimer´s DiseaseNCT01524887 · 508 enrolled · United States, Australia, Belgium and more
- Nov 27, 2012Phase 3 study in Alzheimer´s DiseaseNCT01736579 · 6 enrolled · United States
- Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesNCT03116347 · 42 enrolled · Czechia, Denmark, France and more
- Apr 10, 2020Phase 3 study in Primary Immunodeficiency DiseasesNCT04346108 · 17 enrolled · Japan
- Aug 27, 2021Phase 1 study in Healthy VolunteersNCT05059977 · 24 enrolled · United States
- Jan 26, 2023Phase 3 study in Primary Immunodeficiency DiseasesNCT05755035 · 65 enrolled · United States, Czechia, Denmark and more
- Oct 4, 2023Phase 3 study in Primary Immunodeficiency DiseasesNCT06076642 · 53 enrolled · United States, Czechia, Denmark and more
- Dec 19, 2024Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06747351 · 59 planned · United States, Argentina, Czechia and more
- Mar 20, 2025Phase 1 study in Healthy VolunteersNCT06895967 · 30 enrolled · United States
- Apr 11, 2025Phase 1 study in Healthy VolunteersNCT06935266 · 64 enrolled · United States
- May 13, 2025Phase 3 study in Multiple MyelomaNCT06980480 · 183 planned · United States, Australia, Austria and more
Ahead
- May 16, 2028Primary completion: phase 3 study in Primary Immunodeficiency DiseasesNCT06076642
- Jun 25, 2028Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT06747351
- Sep 11, 2028Primary completion: phase 3 study in Multiple MyelomaNCT06980480
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 20 Takeda leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06980480Multiple Myeloma · United States, Australia, Austria and more | 3 | Recruiting | Sep 11, 2028 | 183 |
| NCT06935266Healthy Volunteers · United States | 1 | Completed | Sep 27, 2025 | 64 |
| NCT06895967Healthy Volunteers · United States | 1 | Completed | Jul 24, 2025 | 30 |
| NCT06747351Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Czechia and more | 3 | Recruiting | Jun 25, 2028 | 59 |
| NCT06076642Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more | 3 | Active, not recruiting | May 16, 2028 | 53 |
| NCT05755035Primary Immunodeficiency Diseases · United States, Czechia, Denmark and more | 3 | Completed | Jan 20, 2026 | 65 |
| NCT05059977Healthy Volunteers · United States | 1 | Completed | Apr 12, 2022 | 24 |
| NCT04346108Primary Immunodeficiency Diseases · Japan | 3 | Completed | Dec 22, 2021 | 17 |
| NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more | 4 | Completed | Jan 15, 2021 | 42 |
| NCT01736579Alzheimer´s Disease · United States | 3 | Terminated | Jun 4, 2013 | 6 |
| NCT01524887Alzheimer´s Disease · United States, Australia, Belgium and more | 3 | Terminated | Jul 16, 2013 | 508 |
| NCT01412385Primary Immunodeficiency Diseases · Austria, Germany, Hungary and more | 3 | Completed | May 13, 2014 | 55 |
| NCT01218438Primary Immunodeficiency Diseases · United States, Canada | 3 | Completed | Mar 13, 2015 | 86 |
| NCT00818662Dementia · United States, Canada | 3 | Completed | Dec 10, 2012 | 390 |
| NCT00782106Primary Immunodeficiency Diseases · United States | 2 | Completed | Nov 1, 2007 | 11 |
| NCT00666263Multifocal Motor Neuropathy · United States, Canada, Denmark | 3 | Completed | Aug 11, 2011 | 50 |
| NCT00546871Primary Immunodeficiency Diseases · United States | 3 | Completed | Jul 1, 2009 | 49 |
| NCT00162006Purpura, Thrombocytopenic, Idiopathic · Czechia, Germany, Hungary and more | 2 | Completed | Dec 3, 2003 | 28 |
| NCT00161993Primary Immunodeficiency Diseases · Finland, Sweden | 2 | Completed | Sep 24, 2003 | 24 |
| NCT00157079Primary Immunodeficiency Diseases · United States | 3 | Completed | Dec 16, 2003 | 61 |
How it is read
Names in the registry
- “NPB-01”, 7 entries
- “TAK-881”, 6 entries
- “IVIG”, 6 entries
- “Kedrion IVIG 10%”, 4 entries
- “GB-0998”, 4 entries
Codes read as this program: TAK881, GC5107, GB0998.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 24 studies
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 5 studies
- Immunologic Deficiency Syndromes, 4 studies
- Myasthenia Gravis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.